Urinary lead exposure and breast cancer risk in a population-based case-control study

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 9, 2008, Pages 2311-2317

  McElroy, Jane A ^a,g   Shafer, Martin M ^b   Gangnon, Ronald E ^c   Crouch, Luis A ^f   Newcomb, Polly A ^d,e  

^a University of Missouri   (United States)

^b Environmental Chemistry and Technology Program

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

^e USA   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

^g UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; LEAD;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; EXPOSURE; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PRIORITY JOURNAL; URINE;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LEAD; LOGISTIC MODELS; MIDDLE AGED; QUESTIONNAIRES; REGISTRIES; TUMOR MARKERS, BIOLOGICAL; WISCONSIN;

EID: 53349176784     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0263     Document Type: Article

References (51)

1. Thomas VM, Socolow RH, Fanelli JJ, Spiro TG. Effects of reducing lead in gasoline: an analysis of the international experience. Environ Sci Technol 1999;33:3942-8.
2. Landrigan PJ, Boffetta P, Apostoli P. The reproductive toxicity and carcinogenicity of lead: a critical review. Am J Ind Med 2000;38:231-43.
3. Agency for Toxic Substances and Disease Registry. Toxicological profile for lead. Atlanta (GA): U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry; 2007.
4. IARC Working Group on the evaluation of carcinogenic risks to humans. Inorganic and organic lead compounds. IARC Monogr Eval Carcinog Risks Hum 2006;87:1-471.
5. Silbergeld EK. Facilitative mechanisms of lead as a carcinogen. Mutat Res 2003;533:121-33.
6. Jarup L. Hazards of heavy metal contamination. Br Med Bull 2003;68:167-82.
7. Paschal DC, Ting BG, Morrow JC, et al. Trace metals in urine of United States residents: reference range concentrations. Environ Res 1998;76:53-9.
8. Pawasarat J. The driver license status of the voting age population in Wisconsin. Milwaukee (WI): University of Wisconsin-Milwaukee Employment and Training Institute; 2005. [accessed 2008 January 3]. Available from: http://www.uwm.edu/Dept/ETI/barriers/DriversLicense.pdf.
9. Centers for Disease control and Prevention (CDC), National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data (NHANES), 2003-2004. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; [accessed 2008 June 3]. Available from: http://www.cdc.gov/nchs/about/major/nhanes/nhanes2003-2004/ nhanes03_04.htm.
10. Shafer M, Overdier J. Analysis of surface waters for trace elements by inductively coupled plasma mass spectrometry. Lake Michigan Mass Balance methods compendium. Volume 3. Metals, conventionals, radiochemistry, and biomonitoring sample analysis techniques. Chicago (IL): U.S. Environmental Protection Agency, Great Lakes National Program Office; 1997. p. 3-85-3-129.
11. Elinder CG. Normal values for cadmium in human tissues, blood, and urine in different countries. In: Friberg L, Elinder CG, Kjellstrom T, Nordberg GF, editors. Cadmium and health: a toxicological and epidemiological appraisal, volume I exposure, dose, and metabolism. Boca Raton (FL): CRC Press; 1985. p. 81-102.
12. Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, Pirkle JL. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ Health Perspect 2005;113:192-200.
13. Mason HJ, Williams NR, Morgan MG, Stevenson AJ, Armitage S. Influence of biological and analytical variation on urine measurements for monitoring exposure to cadmium. Occup Environ Med 1998;55:132-7.
14. Haddow JE, Knight GJ, Palomaki GE, Neveux LM, Chilmonczyk BA. Replacing creatinine measurements with specific gravity values to adjust urine cotinine concentrations. Clin Chem 1994;40:562-4.
15. Rizk SL, Sky-Peck HH. Comparison between concentrations of trace elements in normal and neoplastic human breast tissue. Cancer Res 1984;44:5390-4.
16. Mulay IL, Roy R, Knox BE, Suhr NH, Delaney WE. Trace-metal analysis of cancerous and noncancerous human tissues. J Natl Cancer Inst 1971;47:1-13.
17. Tariq MA, Qamar un N, Fatima A. Concentrations of Cu, Cd, Ni, and Pb in the blood and tissues of cancerous persons in a Pakistani population. Sci Total Environ 1995;175:43-8.
18. Santoliquido PM, Southwick HW, Olwin JH. Trace metal levels in cancer of the breast. Surg Gynecol Obstet 1976;142:65-70.
19. Schwartz AE, Leddicotte GW, Fink RW, Friedman EW. Trace elements in normal and malignant human breast tissue. Surgery 1974;76:325-9.
20. Cake KM, Bowins RJ, Vaillancourt C, et al. Partition of circulating lead between serum and red cells is different for internal and external sources of lead. Am J Ind Med 1996;29:440-5.
21. Gulson BL, Mahaffey KR, Mizon KJ, Korsch MJ, Cameron MA, Vimpani G. Contribution of tissue lead to blood lead in adult female subjects based on stable lead isotope methods. J Lab Clin Med 1995;125:703-12.
22. Hernandez-Avila M, Smith D, Meneses F, Sanin LH, Hu H. The influence of bone and blood lead on plasma lead levels in environmentally exposed adults. Environ Health Perspect 1998;106:473-7.
23. Smith DR, Osterloh JD, Flegal AR. Use of endogenous, stable lead isotopes to determine release of lead from the skeleton. Environ Health Perspect 1996;104:60-6.
24. Hu H, Shih R, Rothenberg S, Schwartz BS. The epidemiology of lead toxicity in adults: measuring dose and consideration of other methodologic issues. Environ Health Perspect 2007;115:455-62.
25. Ambrose TM, Al Lozi M, Scott MG. Bone lead concentrations assessed by in vivo X-ray fluorescence. Clin Chem 2000;46:1171-8.
26. Rabinowitz MB. Toxicokinetics of bone lead. Environ Health Perspect 1991;91:33-7.
27. Smith D, Hernandez-Avila M, Tellez-Rojo MM, Mercado A, Hu H. The relationship between lead in plasma and whole blood in women. Environ Health Perspect 2002;110:263-8.
28. Ong CN, Lee WR. Distribution of lead-203 in human peripheral blood in vitro. Br J Ind Med 1980;37:78-84.
29. Barbosa F, Jr., Tanus-Santos JE, Gerlach RF, Parsons PJ. A critical review of biomarkers used for monitoring human exposure to lead: advantages, limitations, and future needs. Environ Health Perspect 2005;113:1669-74.
30. Bergdahl IA, Schutz A, Gerhardsson L, Jensen A, Skerfving S. Lead concentrations in human plasma, urine and whole blood. Scand J Work Environ Health 1997;23:359-63.
31. Fukui Y, Miki M, Ukai H, et al. Urinary lead as a possible surrogate of blood lead among workers occupationally exposed to lead. Int Arch Occup Environ Health 1999;72:516-20.
32. Gulson BL, Cameron MA, Smith AJ, et al. Blood lead-urine lead relationships in adults and children. Environ Res 1998;78:152-60.
33. Tsaih SW, Schwartz J, Lee ML, et al. The independent contribution of bone and erythrocyte lead to urinary lead among middle-aged and elderly men: the normative aging study. Environ Health Perspect 1999;107:391-6.
34. Barry PS. A comparison of concentrations of lead in human tissues. Br J Ind Med 1975;32:119-39.
35. Manton WI. Significance of lead isotope composition in blood. Nature 1973;244:165-7.
36. Shen XM, Yan CH, Guo D, et al. Low-level prenatal lead exposure and neurobehavioral development of children in the first year of life: a prospective study in Shanghai. Environ Res 1998;79:1-8.
37. Paschal DC, Burt V, Caudill SP, et al. Exposure of the U.S. population aged 6 years and older to cadmium: 1988-1994. Arch Environ Contam Toxicol 2000;38:377-83.
38. Magos L. Epidemiological and experimental aspects of metal carcinogenesis: physicochemical properties, kinetics, and the active species. Environ Health Perspect 1991;95:157-89.
39. Webber CE, Chettle DR, Bowins RJ, et al. Hormone replacement therapy may reduce the return of endogenous lead from bone to the circulation. Environ Health Perspect 1995;103:1150-3.
40. Gulson BL, Mizon KJ, Korsch MJ, Palmer JM, Donnelly JB. Mobilization of lead from human bone tissue during pregnancy and lactation-a summary of long-term research. Sci Total Environ 2003;303:79-104.
41. Hernandez-Avila M, Gonzalez-Cossio T, Palazuelos E, et al. Dietary and environmental determinants of blood and bone lead levels in lactating postpartum women living in Mexico City. Environ Health Perspect 1996;104:1076-82.
42. Korrick SA, Schwartz J, Tsaih SW, et al. Correlates of bone and blood lead levels among middle-aged and elderly women. Am J Epidemiol 2002;156:335-43.
43. Nash D, Magder LS, Sherwin R, Rubin RJ, Silbergeld EK. Bone density-related predictors of blood lead level among peri- and postmenopausal women in the United States: The Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2004;160:901-11.
44. Miki Y, Suzuki T, Sasano H. Aromatase inhibitor and bone. Biomed Pharmacother 2007;61:540-2.
45. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
46. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
47. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57.
48. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619-29.
49. Coleman RE, Body JJ, Gralow JR, Lipton A. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. Cancer Treat Rev 2008;34 Supplement 1:S31-42.
50. Waltman NL, Ott CD, Twiss JJ, Gross GJ, Lindsey AM, Moore TE. Bone mineral density and bone turnover in postmenopausal women treated for breast cancer. Cancer Nurs 2008;31:182-90.
51. Ramaswamy B, Shapiro CL. Osteopenia and osteoporosis in women with breast cancer. Semin Oncol 2003;30:763-75.